Log in

NASDAQ:OVAS - OvaScience Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
$8.56
MA: $12.74
$17.10
52-Week Range N/A
Volume92,099 shs
Average Volume163,131 shs
Market Capitalization$306.71 million
P/E RatioN/A
Dividend YieldN/A
Beta3.11
OvaScience, Inc, a fertility company, discovers, develops, and commercializes fertility treatment options for women and families struggling with infertility worldwide. Its patented technology is based on the discovery about the existence of egg precursor (EggPC) cells to transform the treatment landscape for women's fertility. The company offers various fertility treatment options, including OvaPrime treatment to restore a woman's egg production by isolating a woman's own EggPC cells within her ovary to mature in vivo into healthy and fertilizable eggs; OvaTure treatment to mature EggPC cells into fertilizable eggs in vitro or outside the body by eliminating the need for hormone stimulation; and AUGMENT treatment to enhance the fertilization and pregnancy rates by using mitochondria from a woman's own EggPC cells. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OVAS
CUSIPN/A
Phone617-500-2802

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$290,000.00
Book Value$1.80 per share

Profitability

Net Income$-50,970,000.00
Net Margins-10,128.37%

Miscellaneous

EmployeesN/A
Market Cap$306.71 million
Next Earnings DateN/A
OptionableOptionable

Receive OVAS News and Ratings via Email

Sign-up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter.


OvaScience (NASDAQ:OVAS) Frequently Asked Questions

What is OvaScience's stock symbol?

OvaScience trades on the NASDAQ under the ticker symbol "OVAS."

Has OvaScience been receiving favorable news coverage?

Media coverage about OVAS stock has been trending positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OvaScience earned a daily sentiment score of 2.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for OvaScience.

Who are some of OvaScience's key competitors?

What other stocks do shareholders of OvaScience own?

Who are OvaScience's key executives?

OvaScience's management team includes the folowing people:
  • Dr. Christopher A. Kroeger M.D., MBA, CEO, Pres, Sec. & Director (Age 50)
  • Dr. Michelle Dipp, Co-Founder & Advisor (Age 42)
  • Mr. Jonathan Gillis, Sr. VP of Fin. & Treasurer (Age 37)
  • Dr. Jonathan L. Tilly Ph.D., Co-Founder and Advisor (Age 55)
  • Ms. Katherine Pare Lefeber, VP of Strategy & Operations

How big of a company is OvaScience?

OvaScience has a market capitalization of $0.00 and generates $290,000.00 in revenue each year. View Additional Information About OvaScience.

What is OvaScience's official website?

The official website for OvaScience is http://www.ovascience.com/.

How can I contact OvaScience?

OvaScience's mailing address is 9 FOURTH AVENUE, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 617-500-2802 or via email at [email protected]


MarketBeat Community Rating for OvaScience (NASDAQ OVAS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  291 (Vote Underperform)
Total Votes:  561
MarketBeat's community ratings are surveys of what our community members think about OvaScience and other stocks. Vote "Outperform" if you believe OVAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: Capital Gains

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel